Domatinostat in combination with pembrolizumab is currently being evaluated in patients with advanced cutaneous melanoma primary refractory or nonresponding to anti-PD-1 therapy (SENSITIZE trial: NCT03278665; completion expected Dec 2020). Here, PDCD1 is linked to cutaneous melanoma.